

# Accelerating global development with an Asian oncology platform

ASLAN Pharmaceuticals is a clinical-stage oncology-focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe

## Developing in Asia for global markets

- Strategically positioned in Asia with access to larger patient population where target cancers are prevalent
- Development platform in Asia enables acceleration of drug development and generation of data suitable for submission to regulators in US, Europe and Japan
- Experienced global management team with deep local relationships and extensive knowledge of target diseases
- Few, if any, approved therapies in biliary tract cancer and gastric cancer
- Building commercial organisation in China and planning to build in US

## Quick facts

### Ticker

- NASDAQ: ASLN
- TPEX: 6497

(Each US ADS equivalent to 5 TPEX common shares)

### Shares outstanding

160,128,940

### Market Cap

US\$259M

(28 August 2018, NASDAQ)

### Cash

US\$45M

(30 June 2018)

## Varlitinib (ASLAN001)

Potential to be the first targeted therapy approved for biliary tract cancer and first-line treatment for HER1/HER2 coexpressing gastric cancer

- Highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2, HER3 and HER4
- Demonstrated activity in biliary tract, gastric, breast and colorectal cancer. Two phase 2 trials completed, over 400 patients dosed
- Low levels of toxicity compared to other pan-HER inhibitors
- Competitive efficacy with 60% response rate demonstrated in second line HER2+ breast cancer
- Currently no approved targeted therapies for biliary tract cancer which affects more than 200,000 people in Asia every year
- Received Orphan Drug Designation from the US FDA for biliary tract cancer and gastric cancer
- Gastric cancer: phase 2 recruitment completed in Aug 2018, readout expected by 4Q18
- Biliary tract cancer: pivotal TreeTopp trial enrolment completion expected in early 2019, topline data expected in 2019

## ASLAN003

Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

- Potent inhibition of DHODH, binding affinity up to two orders of magnitude stronger than first generation inhibitors
- Promotes differentiation of blast cells in multiple cell lines that are unresponsive to ATRA
- Lack of toxicities associated with first generation inhibitors and other AML therapies
- Received Orphan Drug Designation from the US FDA for AML
- Interim data from phase 2 trial in relapsed or refractory AML patients expected in the second half of 2018
- Preclinical studies in triple negative breast cancer and hepatocellular carcinoma underway

## ASLAN004

A fully human monoclonal antibody with a potential to be a first-in-class IL-13R $\alpha$ 1 inhibitor

- Potently inhibits signaling of both IL-4 and IL-13 receptors which are central to the allergic response in atopic dermatitis and asthma
- By targeting IL-13R $\alpha$ 1, a receptor with a narrower cellular distribution than the IL-4 receptor, it has the potential to offer both a lower dose and lower dosing frequency than current alternatives for target indications
- Clinical trial authorisation application submitted to Singapore Health Sciences Authority (HSA) in July 2018
- Phase 1 clinical trial for ASLAN004 to be initiated in asthma and atopic dermatitis in 2H2018

Programs	Discovery	Preclinical	Phase 1	Phase 2	Pivotal	Key Milestones
<b>Global rights</b>						
<b>Varlitinib</b> <i>Pan-HER inhibitor</i>	Biliary tract cancer					Global pivotal topline data (2nd line) 2019 Phase 1b data (1st line) 4Q18 Phase 2 topline data 4Q18
	Gastric cancer					
	Breast cancer					
	Colorectal cancer					
<b>ASLAN003</b> <i>DHODH inhibitor</i>	AML					Interim data 4Q18
<b>ASLAN004</b> <i>IL4R/IL13R inhibitor</i>	Atopic dermatitis					
	Asthma					
<b>Preclinical programs</b>	Oncology					
<b>Partnered programs</b>						
<b>ASLAN002</b> <i>RON/MET inhibitor</i> <i>Partnered with BMS</i>	Solid tumors					

## Management

**Dr Carl Firth**  
Chief Executive Officer

**Dr Bertil Lindmark**  
Chief Medical Officer

**Dr Mark McHale**  
Chief Operating Officer

**Jeff Tomlinson**  
Chief Business Officer

**Ben Goodger**  
General Counsel

**Kiran Asarpota**  
VP Finance

**Stephen Doyle**  
VP Commercial and GM China

**Dr Chih-Yi Hsieh**  
VP Medical and GM Taiwan

## Major partnerships



## Analyst coverage

**Edward Tenthoff**  
Piper Jaffray

**Jonathan Chang**  
Leerink Partners

**Raghuram Selvaraju**  
H C Wainwright & Co

**Robert Hazlett**  
BTIG

**John Chang**  
President Capital Management Corp

## Headquarters

83 Clemenceau Avenue  
#12-03 UE Square  
Singapore 239920  
+65 6222 4235  
contact@aslanpharma.com

## Investor contact

**Robert Uhl**  
Westwicke Partners  
+1 858 356 5932  
robert.uhl@westwicke.com

## Investor contact (Taiwan)

**Michael Chiang**  
ASLAN Pharmaceuticals  
+886 2 2758 2767  
investor-taiwan@aslanpharma.com

## Media contact

**Emma Thompson**  
Spurwing Communications  
+65 6340 7287  
emma@spurwingcomms.com